ConductScience.org, home
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
API referenceFor AI assistants

Trial · NCT02807844

Adverse events2,560

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 2,560

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherAnaemiaBlood and lymphatic system disordersPh Ib: MCS110@1 mg/kg Q3W@+ PDR001 100@mg Q3W46
otherAnaemiaBlood and lymphatic system disordersPh Ib: MCS110@3 mg/kg Q3W@+ PDR001 100@mg Q3W212
otherAnaemiaBlood and lymphatic system disordersPh Ib: MCS110@3 mg/kg Q3W@+ PDR001 300@mg Q3W312
otherAnaemiaBlood and lymphatic system disordersPh Ib: MCS110@5 mg/kg Q3W@+ PDR001 300@mg Q3W313
otherAnaemiaBlood and lymphatic system disordersPh Ib: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W36
otherAnaemiaBlood and lymphatic system disordersPh Ib: MCS110@10 mg/kg Q3W@+ PDR001 300@mg Q3W311
otherAnaemiaBlood and lymphatic system disordersPh II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - TNBC420
otherAnaemiaBlood and lymphatic system disordersPh II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - PC620
otherAnaemiaBlood and lymphatic system disordersPh II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - EC521
otherAnaemiaBlood and lymphatic system disordersPh II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - ME720
otherLeukocytosisBlood and lymphatic system disordersPh Ib: MCS110@1 mg/kg Q3W@+ PDR001 100@mg Q3W06
otherLeukocytosisBlood and lymphatic system disordersPh Ib: MCS110@3 mg/kg Q3W@+ PDR001 100@mg Q3W012
otherLeukocytosisBlood and lymphatic system disordersPh Ib: MCS110@3 mg/kg Q3W@+ PDR001 300@mg Q3W012
otherLeukocytosisBlood and lymphatic system disordersPh Ib: MCS110@5 mg/kg Q3W@+ PDR001 300@mg Q3W213
otherLeukocytosisBlood and lymphatic system disordersPh Ib: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W06
otherLeukocytosisBlood and lymphatic system disordersPh Ib: MCS110@10 mg/kg Q3W@+ PDR001 300@mg Q3W011
otherLeukocytosisBlood and lymphatic system disordersPh II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - TNBC020
otherLeukocytosisBlood and lymphatic system disordersPh II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - PC020
otherLeukocytosisBlood and lymphatic system disordersPh II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - EC021
otherLeukocytosisBlood and lymphatic system disordersPh II: MCS110@7.5 mg/kg Q3W@+ PDR001 300@mg Q3W - ME020

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02807844/events

API referenceFor AI assistants